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Abstract 
Introduction: A paucity of data exists on the incidence, diagnosis and treatment of 
bleeding in women with inherited factor VII (FVII) deficiency.  
Aim: Here we report results of a comprehensive analysis from two international 
registries of patients with inherited FVII deficiency, depicting the clinical picture of this 
disorder in women and describing any gender-related differences.  
Methods: A comprehensive analysis of two fully compatible, international registries of 
patients with inherited FVII deficiency (International Registry of Factor VII deficiency, 
IRF7; Seven Treatment Evaluation Registry, STER) was performed. 
Results: In our cohort (N=449; 215 male, 234 female), the higher prevalence of 
mucocutaneous bleeds in females strongly predicted ensuing gynaecological bleeding 
(hazard ratio=12.8, 95% CI 1.68–97.6, P=0.014). Menorrhagia was the most prevalent 
type of bleeding (46.4% of patients), and was the presentation symptom in 12% of 
cases. Replacement therapies administered were also analysed. For surgical procedures 
(n=50), a receiver operator characteristic analysis showed that the minimal first dose of 
rFVIIa to avoid postsurgical bleeding during the first 24 hours was 22 μg/kg, and no 
less than two administrations. Prophylaxis was reported in 25 women with excellent or 
effective outcomes when performed with a total weekly rFVIIa dose of 90 μg/kg 
(divided as three doses).  
Conclusion: Women with FVII deficiency have a bleeding disorder mainly 
characterized by mucocutaneous bleeds, which predicts an increased risk of ensuing 
gynaecological bleeding. Systematic replacement therapy or long-term prophylaxis with 
rFVIIa may reduce the impact of menorrhagia on the reproductive system, iron loss and 
may avoid unnecessary hysterectomies. 
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Introduction 
Autosomal recessive bleeding disorders (ARBDs) occur as frequently in women as in 
men, but women may experience more bleeding than men because the gynaecological 
and obstetric challenges to haemostasis add an important additional burden to the 
background bleeding related to the haemostatic defect. In addition, when tested for 
haemostatic abnormalities, as many as 20% of women with excessive menstrual 
bleeding (menorrhagia) are found to have a bleeding disorder, be it frequent (von 
Willebrand disease [vWD]) or rare [1]. This is because menstruation and ovulation are 
associated with an increased risk of bleeding, as are pregnancy and delivery, or 
gynaecological and endocrine pathologies [1,2].  
Menorrhagia is the most common bleeding symptom in women of reproductive age 
with ARBDs [3-8], represents a very frequent cause of iron deficiency [1,3,6,9-12] and 
carries a high negative impact on the quality of life [2,7]. Furthermore, other frequent 
gynaecological problems, such as uterine fibroids, are more likely to be symptomatic 
because of the increased bleeding tendency. In addition to menorrhagia, irregular 
menstrual cycles, breakthrough spotting, haemorrhagic ovarian cysts and endometriosis 
are other common gynaecological abnormalities reported in women with ARBDs 
[2,3,6]. With reference to the obstetric problems, bleeding may persist throughout 
pregnancy [12], especially when the haemostatic defect is severe. 
Factor VII (FVII) deficiency is an ARBD with an estimated incidence of 1/300 000 to 
1/500 000 in the general population [8,13-15]. The bleeding phenotype of affected 
patients is highly variable, ranging from asymptomatic patients to those who may 
experience life-threatening bleeding episodes [8,13]. Treatment of the most frequently 
occurring gynaecological conditions is mostly based on the limited experience of each 
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treating centre or on infrequent reports. For menorrhagia, the therapy options have 
recently changed from more conservative medical approaches, with antifibrinolytics and 
hormones, to replacement therapy (RT) and prophylaxis [2,15,16]. This shift towards a 
rational, replacement-based approach is likely to change clinical practice that, until 
recently, frequently adopted surgical approaches including endometrial ablation [17] or 
hysterectomy [18].  
Currently, available data also indicate that while FVII plasma levels rise during 
pregnancy in normal women, no such increase is observed in homozygous patients and 
only a moderate rise is observed in heterozygous individuals [12]. As a consequence, 
women with FVII deficiency may develop bleeding not only during pregnancy but also 
postpartum [1,12,13,19].  
Due to the rarity of this autosomally inherited bleeding disorder and the lack of evidence-
based data, we collated and analysed data from two large, fully compatible registries—
Seven Treatment Evaluation Registry (STER) and the International Registry on 
Congenital FVII Deficiency (IRF7); n = 449 patients; the aim of this analysis was to 
describe the reported clinical picture of FVII deficiency in women and highlight any sex-
related differences. In addition, we reviewed the treatment options reported in the STER 
for the bleeds and the most common gynaecological and obstetric bleeding reported. 
Materials and methods  
Data reported for patients with FVII deficiency in IRF7 and STER were analysed using 
the same method as that adopted for a previous study [13]. The primary aim of IRF7 
was to collect and describe data on inherited FVII deficiency clinical phenotype and 
genetic mutations, while STER was intended to describe replacement treatment 
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modalities and outcomes. Both databases gathered homogenous demographic and 
clinical history data on bleeding symptoms (site, frequency, entity, treatment) related to 
two different cohorts of patients with inherited FVII deficiency; thus, they can be 
merged for descriptive purposes. The registry protocols were approved by the 
Institutional Review Board of L’Aquila University Hospital. The STER protocol was 
published on http://clinicaltrials.gov (NCT01269138).  
FVII coagulant activity (FVII:C) measurements were assessed at each participating 
centre. In 98% of the centres, high-sensitivity thromboplastins (International Sensitivity 
Index ≈ 1) were employed. Screening for inhibitors to FVII was performed at a central 
laboratory [20].  
As FVII:C levels higher than 26% have an uncertain clinical relevance to bleeding 
events [21], individuals with FVII:C >26% were excluded from the analyses. Patients 
were classified in accordance to previously published criteria into residual FVII:C 
subgroups (<3%, 3–26%, >26%) and also by clinical phenotype as either major 
bleeders, minor bleeders or asymptomatic patients [13].  
Surgical procedures were classified as either minor or major according to standard 
criteria [22]. For each procedure, the following data about RT schedule were evaluated: 
(i) RT duration (days), (ii) number of RT injections, (iii) first dose and (iv) total RT 
dose per day. 
As the majority of RT was performed with rFVIIa (Novoseven®, Novo Nordisk, 
Bagvaerd, Denmark), efficacy evaluation was limited to this RT type and according to 
the following criteria:  
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- Excellent: Single administration leading to cessation of overt bleeding and of 
related symptoms; prompt (within a few hours) relief of pain; disappearance 
of swelling and return to the previous range of joint or limb mobility. 
Cessation of bleeding was also evaluated by imaging if appropriate. In the 
case of prophylaxis: no bleeds in between the doses. 
- Effective: More than one administration was needed to obtain the same 
results as above. In the case of prophylaxis: >50% reduction in the number 
of bleeds. 
- Partially effective: More than one administration was needed, but symptoms 
subsided slowly and the return of limb and joint mobility was partial. In the 
case of prophylaxis: <50% reduction of the number of bleeds. 
- Ineffective: No changes. 
- Not evaluable: No elements for evaluation.  
 
Statistical analysis 
Data obtained from the two databases were analysed following a quality and 
consistency check of each value. Continuous data were expressed as mean ± standard 
deviation and categorical variables as percent. Continuous variables were compared 
using an independent sample t-test. For data with a skewed distribution, non-parametric 
tests were used. The chi-square test was employed to analyse categorical data. A Cox 
regression analysis was used to determine the risk (hazard ratio [HR]) of developing any 
gynaecological bleed according to FVII:C. A logistic regression model was also used to 
explore whether lifelong gynaecological bleeding may be predicted by the type of 
bleeding presented at the time of FVII deficiency diagnosis. For surgery, as all bleeding 
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episodes occurred during the first postoperative day, the receiver operating 
characteristic analysis was performed for the first dose, number of doses and the total 
dose given on the first day, with a sensitivity set at 100%. All results are expressed as 
two-tailed values with statistical significance reported as P < 0.05. Statistical analysis 
was performed with the SPSS 16 system (SPSS Inc., Chicago, IL, USA). Due to the 
exploratory nature of the study, correction for multiple tests was not conducted. 
Results  
Bleeding phenotype and gender comparisons 
A complete merging of both databases included 755 patients, after the exclusion of 
cases not reporting the variables analysed, 449 patients (215 males, 234 females) were 
included in the current analysis. Table 1 reports the clinical and demographic 
characteristics of the study population. A significant difference in FVII:C levels was 
observed between men and women. Another significant difference was noted in the 
distributions of the clinical severity classes, both at presentation and with reference to 
the lifelong analysis.  
As shown in Table 2, women who experienced gynaecological bleeding were diagnosed 
with FVII deficiency earlier and had significantly lower FVII:C than did women 
without gynaecological bleeding. The association between gynaecological bleeding and 
the other mucous membrane-related bleeds is also shown in Table 2. In addition, a 
multivariate analysis confirmed this association and showed that, after adjusting for age, 
age at diagnosis, age at first symptom and residual FVII levels, a history of gum bleeds, 
epistaxis and easy bruising (excluding the most severe bleeds, where a lifespan up to the 
age of menarche is rarely achieved) is a strong predictor of ensuing gynaecological 
bleeding with an HR of 12.8 for minor and 18.6 for major bleeders. 
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The impact of FVII:C level on the lifelong gynaecological bleeding-free survival was 
clear; women with <3% FVII:C showed a significant increased risk of lifelong 
gynaecological bleeding compared with those with 3–26% FVII:C (HR = 2.802, 95% 
confidence interval [CI] 1.308–6.002, P = 0.008).  
Surgical procedures 
Sixty-three surgical procedures (26 major, 37 minor) performed in 53 women (mean age 
38.9 ± 22.0 years) were analysed and are summarized in Table 3, which also includes 
the main RT data reported. A total of five perioperative bleeding episodes occurred, all 
in patients with <1% FVII:C. The receiver operating characteristic curve analysis was 
performed on 50 patients who received rFVIIa for RT performed on the first day of 
surgery; this analysis showed that a first dose of 22 µg/kg (area under the curve [AUC] 
= 0.816, CI 0.68–0.91, P = 0.0031) and no less than two administrations (AUC = 0.7, CI 
0.55–0.82, P =  0.024) was the minimal treatment schedule able to avoid excessive 
bleeding. The first day total dose (45 µg/kg), although not significant, supported the 
previous findings (AUC = 0.66, CI 0.51–0.69, P = 0.09). Anti fibrinolytic agents 
(tranexamic acid) were administered as concomitant medication during surgery in 16 
case. 
 
Replacement therapy for spontaneous bleeds and prophylaxis 
Table 4 reports the RT used for episodically occurring bleeds for each type of 
haemorrhage. The analysis, again, was restricted to RTs performed with rFVIIa.  
Anti fibrinolytic agents (tranexamic acid) were administered as concomitant medication 
to control spontaneous bleeding episodes in 6 cases. 
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Prophylaxis regimens were performed in 25 women with FVII deficiency. For those 
patients treated with rFVIIa (n = 15, excluding menorrhagia as an indication for 
prophylaxis), the outcome was excellent (no bleeds reported) or effective (>50% 
reduction of the number of bleeds), with a median dose of 90 μg/kg rFVIIa divided into 
three doses per week [16].  
Discussion 
This paper reports on the first comprehensive study focusing on the clinical and 
therapeutic scenarios of women with a FVII deficiency. In terms of the general 
demographic data, the only significant difference between male and female patients 
with FVII deficiency was FVII:C levels, which were lower in women (Table 1)—a 
finding we have previously reported [8,16], but for which we cannot offer an 
explanation, especially if one takes into account that there is a significantly higher 
prevalence of major bleeders in males (Table 1). This difference between male and 
female patients in severity of bleeding phenotypes was consistent both at disease 
presentation and for the lifelong bleeding analyses. Of note, after exclusion of the 
leading gynaecological symptom in female patients, menorrhagia, a clear difference in 
the clinical phenotype between men and women with FVII deficiency was evident and 
characterized by a higher prevalence of mucocutaneous bleeds in women with FVII 
deficiency than men. 
When considering the lifelong history of women with a FVII deficiency, menorrhagia 
was the most prevalent bleed, present in approximately 50% of patients, slightly lower 
than that reported in vWD [4,5,23]; the same holds for menorrhagia as a presentation 
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symptom in comparison with vWD [2]. However, these differences should be taken 
with caution, given the study type and the subjectivity underlying surveys focused on 
this particular symptom [11,24,25]. Here, all 28 reported to have gynaecological 
bleeding as the first bleeding manifestation (71% related to the menarche) experienced 
recurrences of gynaecological bleeding; for the other 81 women with FVII deficiency 
who had other disease presentations, gynaecological bleeds occurred at different ages 
(range 11–79 years), mostly during the fertile years (75%).  
The occurrence of mucocutaneous bleeds at disease presentation was strongly predictive 
for gynaecological bleeding. This means that a girl who is symptomatic is at very high 
risk (HR = 12.8 for minor and 18.6 for major bleeders) of developing menorrhagia at 
the menarche or afterwards. Therefore, her family should be duly alerted in preparation 
for the menarche. Our analyses found that FVII:C was an important element useful for 
the prediction of gynaecological bleeding. However, the difference between women 
with and without gynaecological symptoms is likely to be explained by determinants 
other than FVII:C levels, possibly endocrine. This possibility makes the role of the 
missing clotting factor levels in determining excessive uterine blood loss in clotting 
disorders unclear; in fact, there is also a high prevalence of menorrhagia in women who 
are haemophilia carriers who, by definition, have intermediate to subnormal FVIII/IX 
levels [4]. 
In our cohort, 26 of the surgical procedures reported in the STER were ‘major’ and 37 
were ‘minor’. For major surgical interventions, a slightly higher first day rFVIIa dose 
was used in comparison with the minor interventions/invasive procedures (39 vs. 32 
μg/kg), but the number of RT administrations (18 vs. 2) was clearly higher, findings 
similar to our previous reports [26,27]. As bleeding complications only occurred during 
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the first 24 postoperative hours and baseline FVII:C levels did not help to predict 
bleeding (all <1%), the analysis restricted to the early RT period showed that non-
bleeders were given a higher first dose (at least 22 µg/kg) and no less than two doses in 
comparison to those patients who had bled. These findings highlight the importance of 
using a sufficiently effective RT schedule during the first 24 postoperative hours to 
prevent postoperative bleeding [26,27].  
Regarding the obstetric and gynaecological interventions reported in our study (n = 9), 
it is of interest that four of these were hysterectomies with or without ovariectomy. The 
issue of hysterectomy in bleeding disorders is not a negligible one [2,28,29], with most 
of the available data coming from women with vWD; in a case-control study [29], 26% 
of women had undergone a hysterectomy procedure compared with 9% of the controls. 
Of note, pathological specimens from women with longstanding menorrhagia often 
reveal uterine fibroids, endometrial hyperplasia and polyps, together with a high 
prevalence of endometriosis [2]. The most plausible cause of the latter complication was 
postulated to be due to retrograde menstrual flow [30,31].  
In our cohort, postpartum bleeding was reported in four women (median age 21.13 
years; range: 19–33; FVII:C range: 3.4–12.0%). However, as we do not have a 
denominator (number of deliveries), we were unable to calculate the incidence of this 
bleeding event. Recently, a systematic review on 94 deliveries in women with FVII 
deficiency [32] reported a 13% incidence of postpartum bleeding in women who did not 
receive prophylaxis with rFVIIa (higher in caesarean sections than in vaginal deliveries) 
vs. 10% of those who were given RT; the lack of a significant difference led the authors 
to conclude that in this clinical setting, prophylaxis should not be considered as 
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mandatory, but an individualized approach should be used based on the response to 
previous haemostatic challenges and the mode of delivery.  
Spontaneous bleeding episodes (Table 4) were grouped by type; most of the bleeds 
(menorrhagia, haemarthrosis, epistaxis and hematomas) were treated for 1 day with a 
total rFVIIa dose ranging from 30–45 μg/kg with either excellent (one dose) or effective 
(more than one dose) outcomes. Hence, these findings confirm our previous suggestion 
[15] that RT schedules based on 1 day and intermediate rFVIIa doses can be safely 
proposed for these common bleeds. Due to the small number of life-threatening bleeds 
in our cohort (in particular, CNS bleeds), these data do not allow any recommendation 
on the protocols to use for these events. However, such severe bleeds require 
individualized long-term, high-dose treatments, and we believe that prophylaxis should 
be recommended as soon as possible [16].  
The efficacy of antifibrinolytic agents in menorrhagia, either alone or compared with 
other medical interventions, has been recently reviewed [33] and showed a greater 
efficacy of these agents as compared with other interventions (including the oral luteal 
phase progestagens), but not intrauterine administration of levonorgestrel. Oral 
progestagens, combined hormonal contraceptives and the levonorgestrel intrauterine 
system are currently proposed as a first conservative therapeutic choice in women with 
bleeding disorders [2], although no comparative trials against antifibrinolytics in 
congenital bleeding have been conducted. In our study, RT was employed mostly without 
antifibrinolytics and no difference in outcome was observed with the combined use.  
Of note, ‘prophylaxis’ carried out in women with FVII deficiency suffering from 
menorrhagia with replacement treatment given either on day 1 or the first 2 days of the 
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menses for long periods of time (up to 178 months in one patient) yielded excellent 
results, in keeping with our previous findings in which prophylaxis reduced blood losses 
by up to 80% [11]. One then questions why this should not be the current strategy for 
women with ARBD and menorrhagia when this very common bleed occurs from the 
menarche, and no endocrine abnormalities are found. This treatment strategy has a low 
cost, improves the quality of life and may reduce secondary gynaecological 
complications without interfering with fertility. The ultimate goal could be that of 
reducing or abolishing the practice of hysterectomy as a mean for controlling 
gynaecological bleeding.  
Finally, a total of five adverse events were recorded in four patients: one inhibitor [20], 
three re-bleeding episodes (unrelated to therapy as these occurred 4 weeks after 
treatment) and one event of facial nerve paresis (possibly unrelated to therapy). 
Considering the number of patients, the array of clinical bleeds and the large number of 
administrations, RT, at least in this setting, may be considered very safe. 
Conclusion 
We have provided evidence that women with FVII deficiency have a bleeding disorder 
mainly characterized by mucocutaneous haemorrhage. Hence, the differential diagnosis 
against other ARBDs cannot be done on the basis of the bleeding history. Mucocutaneous 
bleeding was associated with a high risk of gynaecological bleeding during and after the 
menarche. FVII:C levels of <3% was a further predictor of gynaecological bleeding. 
Systematic replacement therapy or long-term prophylaxis appears to reduce the impact 
of menorrhagia on the reproductive system, reduce iron loss and may avoid unnecessary 
hysterectomies. 
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Table 1. Clinical and demographic characteristics of the study population. 
General Males 
(n = 215) 
Females 
(n = 234) 
P 
Age, years 29.0 ± 21.3 
(median: 24, range:  
1–86) 
31.1 ± 20.5 
(median: 27.5, range: 
1–86) 
0.197* 
Age at diagnosis, years 16.4 ± 18.5 
(median: 8.01, range: 
1–79.9) 
18.8 ± 17.2 
(median: 13.7, range: 
1–77.8) 
0.084* 
Age at first symptom, 
years 
12.2 ± 17.4 
(median: 4.69, range: 
1–80) 
12.0 ± 15.1 
(median: 6.3, range:  
1–77.8) 
0.133* 
FVII:C levels, % 7.72 ± 7.76 
(median: 3.4, range: 
0.01–25.0) 
4.99 ± 6.40 
(median: 2.0, range: 
0.01–25.0) 
<0.001* 
Presentation, n (%)    
Asymptomatic 73 (34.0) 49 (20.9) 
<0.001 Minor bleeders 96 (44.7) 157 (67.1) 
Major bleeders 46 (21.4) 28 (12.0) 
GI 10 (4.7) 9 (3.8) 0.815 
CNS 28 (13.0) 11 (4.7) 0.002 
Haemarthrosis 8 (3.7) 8 (3.4) 1.000 
Umbilical 6 (2.8) 9 (3.8) 0.606 
Rectal 7 (3.3) 1 (0.4) 0.031 
Hematoma 3 (1.4) 8 (3.4) 0.225 
Menorrhagia – 28 (12.0) – 
Haematuria 2 (0.9) 0 0.229 
Gum bleed 4 (1.9) 13 (5.6) 0.048 
Epistaxis 44 (20.5) 56 (23.9) 0.427 
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Easy bruising  9 (4.2) 13 (5.6) 0.522 
Other 1 (0.5) 4 (1.7) 0.374 
Postsurgical 20 (9.3) 25 (10.7) 0.641 
Lifelong, n (%)    
Asymptomatic 72 (33.5) 43 (18.4)  
<0.001 
Minor bleeders 68 (31.6) 121 (51.7) 
Major bleeders 75 (34.9) 70 (29.9) 
GI bleeding 26 (12.1) 27 (11.5) 0.884 
CNS bleeding 34 (15.8) 19 (8.1) 0.013 
Haemarthrosis 46 (21.4) 39 (16.7) 0.228 
Hematoma 34 (15.8) 51 (21.8) 0.118 
Menorrhagia – 109 (46.6) – 
Haematuria 13 (6.0) 14 (6.0) 1.000 
Gum bleed 43 (20.0) 85 (36.3) <0.001 
Epistaxis 82 (38.1) 105 (44.9) 0.152 
Easy bruising  53 (24.7) 95 (40.6) <0.001 
Postsurgical 21 (9.7) 29 (12.4) 0.468 
FVII:C, factor VII coagulant activity; GI, gastrointestinal; CNS, central nervous system. 
*P for non-parametric comparisons (Mann–Whitney test).  
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Table 2. Univariate analysis of lifelong bleeding episodes in women with and without 
gynaecological bleeding. 
General Gynaecological 
bleeding 
(n = 109) 
No gynaecological 
bleeding 
(n = 125) 
P 
Age, years 23.9 ± 20.5 
(median: 16.0, range: 
1–79) 
39.2 ± 17.3 
(median: 40, range: 
11–86) 
<0.001* 
Age at diagnosis, years 14.2 ± 15.5 
(median: 7.43, range: 
1–68.8) 
22.8 ± 17.6 
(median: 20.0, range: 
1–77.8) 
0.002* 
Age at first symptom, 
years 
11.2 ± 15.2 
(median: 5.24, range: 
1–68.8) 
12.9 ± 14.8 
(median: 7.64, range: 
1–77.8) 
0.043* 
Residual FVII, % 3.7 ± 5.27 
(median: 1.4, range: 
0.01–25) 
6.11 ± 7.08 
(median: 2.7, range: 
0.01–25.0) 
0.004* 
Lifelong, n (%) 
   
Major bleeders 27 (24.8) 43 (34.4) <0.001 
Minor bleeders 82 (75.2) 39 (31.2) 
GI bleeding 8 (7.3) 19 (15.2) 0.067 
CNS bleeding 7 (6.4) 12 (9.6) 0.474 
Haemarthrosis 18 (16.5) 21 (16.8) 1.000 
Haematoma 24 (22.0) 27 (21.6) 1.000 
Haematuria 8 (7.3) 6 (4.8) 0.425 
Gum bleed 54 (49.5) 31 (24.8) <0.001 
Epistaxis 65 (59.6) 40 (32.0) <0.001 
Easy bruising  60 (55.0) 35 (28.0) <0.001 
Postsurgical 17 (15.6) 12 (9.6) 0.245 
FVII, factor VII; GI, gastrointestinal; CNS, central nervous system. 
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*P for non-parametric comparisons (Mann–Whitney test).  
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Table 3. Characteristics of surgical procedures performed in female subjects. 
Type of surgery 
Total 
(n = 63) 
Major surgical 
procedures 
(n = 26) 
Minor surgical 
procedures 
(n = 37) 
Surgery data  
Obstetric and gynaecologic* 
9 
9 (6 rFVIIa,  
3 pd-FVII)* 
– 
Orthopaedic 
4 
4 (3 rFVIIa,  
1 pd-FVII) 
– 
Ear, nose and throat 
3 
3 (2 rFVIIa,  
1 pd-FVII) 
– 
General surgery 
6 
6 (5 rFVIIa,  
1 pd-FVII) 
– 
Urologic 2 2 (2 rFVIIa) – 
Cardiac 1 1 (1 rFVIIa) – 
Neurosurgery 1 1 (1 rFVIIa) – 
Oral surgery 
17 – 
17 (15 rFVIIa,  
2 pd-FVII) 
Eye surgery 2 – 2 (2 rFVIIa) 
Endoscopic 
procedures/biopsies 
18 – 
18 (13 rFVIIa,  
5 pd-FVII) 
Treatment data (only 
rFVIIa; median and range) 
(n = 50) (n = 19) (n = 31) 
Number of days  1 (1–9) 1 (1–9) 1 (1–3) 
Number of doses  3 (1–92) 18 (1–34) 2 (1–31) 
Total first day dose  39 (10–3026) 39 (10–3026) 32 (11–400) 
Concomitant antifibrinolytics 28 (56%) 13 (68.4%) 15 (48.3%) 
Prophylaxis with low 
molecular weight heparin 
4 (7.8%) 2 (10.5%) 2 (6.4%) 
Perioperative thrombosis 0  – – 
Perioperative bleeding 5 (10%) – 5 (16.1%)† 
Need for red blood cells 6 (11.8%) 5 (26.3%) 1 (3.2%) 
  27 
In-hospital stay (days) 5.0 (1–22) 8.5 (2–22) 2 (1–12) 
rFVIIa, recombinant factor VIIa; pd-FVII, plasma-derived factor VII. 
*See Table 4 for details. 
†Three with antifibrinolytics, two without. 
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Table 4. Replacement therapy for spontaneous bleeding episodes (doses reported and outcome refer only to rFVIIa treatment). 
Bleeding type 
(number of 
patients)  
Bleeds, 
n 
 
Patient profile Treatment profile 
Age, 
years 
Median 
(range) 
FVII:C, %  
Median 
(range) 
Bleeding 
profile 
Major/ 
minor 
Drug 
Duration 
of RT, 
days  
Median 
(range) 
Number 
of doses 
Median 
(range) 
Total 
dose, 
μg/kg 
Median 
(range) 
Mean 
daily 
dose, 
μg/kg 
Median 
(range) 
Outcome 
Menorrhagia 
(10) 
15 
22  
(11–46) 
<1 (<1–4) 6/9 
14 rFVIIa  
1 pd-FVII 
1  
(1–6) 
2  
(1–8) 
45.5 
(20–
240) 
27.5 
(13–120) 
10 excellent,  
4 effective 
Haemarthrosis 
(8) 
9 
11  
(5–72) 
1.3 (<1–3) 9/0  
8 rFVIIa  
1 FFP 
1  
(1–1) 
1  
(1–7) 
42.5 
(18–
240) 
42.5 
(18–80) 
6 excellent, 1 effective, 
1 partly effective 
Epistaxis and 
gum bleeding 
8 
13  
(5–54) 
1 (<1–2.7) 5/3 
5 rFVIIa 
2 pd-FVII 
1  
(1–1) 
1  
(1–2) 
30 
(26.6–
30 
(26.6–66) 
4 excellent, 1 effective 
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FVII:C, factor VII coagulant activity; RT, replacement therapy; FFP, fresh frozen plasma; pd-FVII, plasma-derived factor VII; rFVIIa, recombinant 
factor VIIa. 
 
(5) 1 FFP 66) 
Haematomas 
(7) (muscle and 
subcutaneous) 
7 
4  
(0.5–59) 
2.1  
(<1–23.6) 
3/4 
5 rFVIIa 
2 FFP 
1  
(1–1) 
2  
(1–3) 
30 
(26–75) 
30  
(26–75) 
4 excellent, 1 effective 
CNS (3) 4 
<1  
(<1–45) 
1 (<1–1) 4/0 
3 rFVIIa 
1 FFP 
12 
(1–15) 
68 
(8–84) 
2.650 
(125–
3710) 
176.7 
(125–
309.2) 
3 effective 
Easy bruising 
(2) 
4 
13  
(7–13) 
2 (1–2.5) 0/4 4 FFP – – – – Not evaluable 
Other (4) 
(GI, haematuria 
haemo-
peritoneum) 
4 
6  
(0.1–25) 
<1 (<1–5) 3/1 
3 rFVIIa 
1 pd-FVII 
2  
(1–11) 
8  
(3–52) 
240 
(90–
1716) 
120 
(90–156) 
3 excellent 
